Antonio Ocejo, MD, discusses supportive care implications from new data comparing ipilimumab/nivolumab in older vs younger ...

The FDA has approved teclistamab (Tecvayli) daratumumab and hyaluronidase-fihj (Darzalex Faspro) for the treatment of patients with relapsed or refractory multiple myeloma following at least 1 line of ...

The most frequent treatment-emergent AEs for belzutifan/lenvatinib were anemia (69.2%), hypertension (58.9%), and diarrhea ...

Patients with resected renal cell carcinoma (RCC) receiving adjuvant durvalumab (Imfinzi) plus tremelimumab-actl (Imjudo) experienced early reductions in patient-reported quality of life (QoL), ...

While the combination of pembrolizumab with standard-of-care (SOC) radiation, and androgen deprivation therapy with or ...

While every patient with cancer will have psychosocial needs, understanding when to assess those needs and what professionals ...

Final phase 3 EORTC 1333/PEACE-3 data show enzalutamide plus radium-223 extends OS and radiographic progression-free survival in mCRPC with bone metastases. Final data from the phase 3 EORTC ...

With the addition of pembrolizumab to standard androgen deprivation therapy and radiation, immune-related adverse events are more likely.

The Oncology Nursing Society (ONS) is developing a skin of color toxicity photo repository with funding from a grant from La ...

Treatment with systemic intravenous olvimulogene nanivacirepvec (Olvi-Vec) led to promising preliminary results in patients with progressive non–small cell lung cancer (NSCLC) and progressive SCLC ...

Neoadjuvant EV plus pembrolizumab significantly improved event-free survival and overall survival vs gemcitabine/cisplatin in the phase 3 KEYNOTE-B15 trial. Neoadjuvant and adjuvant enfortumab vedotin ...

Zongertinib has been granted accelerated approval in NSCLC harboring HER2 TKD mutations as part of the Commissioner’s National Priority Voucher pilot program. The FDA has approved zongertinib ...